US Patent No: 7,368,126

Number of patents in Portfolio can not be more than 2000

Controlled release depot formulations

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods and compositions for systemically or locally administering a beneficialagent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
DURECT CORPORATIONCUPERTINO, CA63

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bannister, Roy Hollister, CA 2 119
Chen, Guohua Sunnyvale, CA 83 1179
Houston, Paul Hayward, CA 6 153
Kameda, Teresa Sunnyvale, CA 1 63
Kleiner, Lothar Los Altos, CA 36 610
Priebe, David Seattle, WA 4 115

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
6,432,438 Biodegradable vehicle and filler 52 2000
 
Nippon Densan Corporation (1)
5,336,057 Micropump with liquid-absorptive polymer gel actuator 32 1993
 
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (1)
5,279,608 Osmotic pumps 98 1991
 
ALZA CORPORATION (12)
4,865,845 Release rate adjustment of osmotic or diffusional delivery devices 156 1987
5,112,614 Implantable delivery dispenser 160 1989
5,057,318 Delivery system for beneficial agent over a broad range of rates 170 1990
5,059,423 Delivery system comprising biocompatible beneficial agent formulation 153 1990
5,137,727 Delivery device providing beneficial agent stability 163 1991
5,209,746 Osmotically driven delivery devices with pulsatile effect 51 1992
5,234,692 Delivery device with a protective sleeve 142 1992
5,234,693 Delivery device with a protective sleeve 143 1992
5,308,348 Delivery devices with pulsatile effect 77 1993
5,456,679 Delivery devices with pulsatile effect 52 1994
5,620,700 Injectable drug delivery system and method 57 1995
2005/0281,879 Excipients in drug delivery vehicles 3 2004
 
ATRIX LABORATORIES, INC. (6)
4,938,763 Biodegradable in-situ forming implants and methods of producing the same 508 1988
5,278,201 Biodegradable in-situ forming implants and methods of producing the same 275 1990
5,599,552 Biodegradable polymer composition 116 1994
5,733,950 Biodegradable in-situ forming implants and methods of producing the same 93 1995
5,780,044 Liquid delivery compositions 128 1996
5,990,194 Biodegradable in-situ forming implants and methods of producing the same 105 1997
 
Southern Research Institute (1)
5,085,866 Method of producing zero-order controlled-released devices 24 1988
 
Alkermes Controlled Therapeutics, Inc. (2)
5,656,297 Modulated release from biocompatible polymers 175 1994
5,654,010 Composition for sustained release of human growth hormone 102 1995
 
REILLY INDUSTRIES, INC. (1)
5,556,905 Physically-modified degradable thermoplastic compositions 17 1994
 
SCHERING CORPORATION (1)
4,853,218 Zinc-protamine-alpha interferon complex 25 1987
 
Monsanto Technology LLC (1)
4,985,404 Prolonged release of biologically active polypeptides 27 1988
 
The Procter & Gamble Company (1)
5,242,910 Sustained release compositions for treating periodontal disease 32 1992
 
The Timken Company (1)
2003/0170,289 Injectable depot compositions and uses thereof 18 2002
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,651,986 Controlled local delivery of chemotherapeutic agents for treating solid tumors 106 1996
 
Betz Laboratories, Inc. (1)
4,443,340 Control of iron induced fouling in water systems 38 1983
 
DURECT CORPORATION (8)
5,151,093 Osmotically driven syringe with programmable agent delivery 31 1990
6,130,200 Gel composition and methods 97 1997
6,331,311 Injectable depot gel composition and method of preparing the composition 96 1997
2003/0180,364 Catheter injectable depot compositions and uses thereof 16 2002
2004/0024,069 Injectable depot compositions and uses thereof 19 2002
2004/0001,889 Short duration depot formulations 33 2003
2004/0022,859 Injectable multimodal polymer depot compositions and uses thereof 19 2003
2005/0106,214 Excipients in drug delivery vehicles 7 2004
 
RADIOMED CORP. (1)
8,320,995 Fiducial marker with rings 7 2007
 
ETHICON, INC. (6)
5,468,253 Elastomeric medical device 368 1993
5,713,920 Elastomeric medical device 127 1995
5,639,851 High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers 24 1995
5,714,551 High strength, melt processable, lactide-rich, poly (lactide-co-p-dioxanone) copolymers 54 1996
5,868,788 High-strength, melt-processable, lactade-rich, poly(lactade-co-p-dioxanone) copolymers 5 1997
6,113,624 Absorbable elastomeric polymer 39 1999
 
MITSUI CHEMICALS, INC. (1)
5,310,865 Polyhydroxycarboxylic acid and preparation process thereof 58 1992
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PIRAMAL HEALTHCARE LIMITED (3)
8,389,467 In situ self-setting mineral-polymer hybrid materials, composition and use thereof 5 2009
8,258,117 Composition and method for the repair and regeneration of cartilage and other tissues 2 2010
* 2011/0086,008 COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES 2 2010
 
PIRAMAL HEALTHCARE (CANADA) LTS. (4)
* 2009/0030,525 METHOD FOR RESTORING A DAMAGED OR DEGENERATED INTERVERTEBRAL DISC 3 2008
8,747,899 Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof 0 2009
8,920,842 Temperature controlled and pH dependent self gelling biopolymeric aqueous solution 0 2009
* 2010/0028,434 Temperature controlled and pH dependent self gelling biopolymeric aqueous solution 0 2009
 
DURECT CORPORATION (2)
* 2006/0141,040 Injectable non-aqueous suspension 19 2005
* 2014/0141,086 Injectable Depot Compositions and Uses Thereof 0 2013
 
ASTRAZENECA PHARMACEUTICALS LP (2)
8,895,033 Sustained release formulations using non-aqueous carriers 0 2009
* 2011/0212,138 SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS 0 2009
 
BIOSYNTECH CANADA, INC. (3)
* 2007/0037,737 Composition and method for the repair and regeneration of cartilage and other tissues 29 2006
* 2010/0029,549 SITU SELF-SETTING MINERAL-POLYMER HYBRID MATERIALS, COMPOSITION AND USE THEREOF 2 2009
* 2010/0021,545 INJECTABLE IN SITU SELF-FORMING MINERAL-POLYMER HYBRID COMPOSITION AND USES THEREOF 3 2009
 
SURMODICS, INC. (1)
9,090,737 Viscous terpolymers as drug delivery platform 0 2008
 
SURMODICS PHARMACEUTICALS, INC. (7)
8,974,808 Elastic implantable composites and implants comprising same 0 2009
8,951,546 Flexible implantable composites and implants comprising same 1 2009
* 2010/0158,978 BIOACTIVE SPRAY COATING COMPOSITIONS AND METHODS OF MAKING AND USES THEREOF 5 2009
* 2010/0160,891 ELASTIC IMPLANTABLE COMPOSITES AND IMPLANTS COMPRISING SAME 6 2009
* 8,920,921 Terpolymer blends and their use as pressure-sensitive adhesives 2 2011
8,900,699 Terpolymer blends and their use as pressure-sensitive adhesives 0 2011
* 2012/0077,028 TERPOLYMER BLENDS AND THEIR USE AS PRESSURE-SENSITIVE ADHESIVES 4 2011
 
ALLERGAN, INC. (7)
* 8,425,929 Sustained release intraocular implants and methods for preventing retinal dysfunction 1 2004
* 2005/0244,479 Sustained release intraocular implants and methods for preventing retinal dysfunction 31 2004
* 2008/0131,485 SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION 16 2007
8,580,292 Sustained release intraocular implants and methods for treating ocular vasculopathies 0 2008
* 2008/0118,549 SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES 10 2008
9,144,543 Sustained release intraocular implants and methods for preventing retinal dysfunction 0 2013
9,138,480 Compositions and methods for stimulating hair growth 0 2014
 
POLYVALOR, LIMITED PARTNERSHIP (1)
* 2009/0075,383 COMPOSITION AND METHOD FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS TO CELLS USING CHITOSAN 4 2006
 
Brookwood Pharmaceuticals (1)
* 2011/0129,422 Viscous Terpolymers as Drug Delivery Platform 5 2011
 
WARSAW ORTHOPEDIC, INC. (2)
* 8,591,935 Methods and compositions for treating pain comprising a statin 0 2011
* 2011/0217,382 Methods and Compositions for Treating Pain Comprising a Statin 0 2011
 
BROOKWOOD PHARMACEUTICALS, INC. (1)
* 2009/0124,535 VISCOUS TERPOLYMERS AS DRUG DELIVERY PLATFORM 9 2008
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 6, 2019
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00